Clinical Trial Update: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of oral abexinostat in patients with relapsed or refractory diffuse large B-cell lymphoma is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Abexinostat (Abexinostat)

Snippet

Sponsor: Xynomic Pharmaceuticals, Inc. | Conditions: Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING